Scholarlink

Background <p>Bipolar androgen therapy (BAT) with supraphysiologic testosterone (SPT) could be a therapeutic platform to keep the “endocrine interference” going in men with castration resistant prostate cancer CRPC Davis ID., et al(N Engl J Med 38:121-31, 2019), Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC (Oncologist 28:465-73, 2023). This concept, scientifically developed by the Johns Hopkins group, has been tested in several clinical trials Denmeade SR, Isaacs JT (Prostate 70:1600-7, 2010).</p> Case presentation <p>This case report details the diagnosis and novel treatment with BAT during the course of disease of a 68-year-old male patient with primary metastatic prostate cancer identified in November 2019. After treatment failure of standard therapy this patient commenced with SPT given intramuscularly at four weeks intervals and concurrent androgen deprivation throughout treatment with BAT (Fig.&#xa0;1). He responded clinically with stable disease and without serious toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月17日

查看全文
  • Wolfgang Lilleby,
  • Hans Geinitz,
  • Samuel Denmeade

摘要

Background

Bipolar androgen therapy (BAT) with supraphysiologic testosterone (SPT) could be a therapeutic platform to keep the “endocrine interference” going in men with castration resistant prostate cancer CRPC Davis ID., et al(N Engl J Med 38:121-31, 2019), Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC (Oncologist 28:465-73, 2023). This concept, scientifically developed by the Johns Hopkins group, has been tested in several clinical trials Denmeade SR, Isaacs JT (Prostate 70:1600-7, 2010).

Case presentation

This case report details the diagnosis and novel treatment with BAT during the course of disease of a 68-year-old male patient with primary metastatic prostate cancer identified in November 2019. After treatment failure of standard therapy this patient commenced with SPT given intramuscularly at four weeks intervals and concurrent androgen deprivation throughout treatment with BAT (Fig. 1). He responded clinically with stable disease and without serious toxicity.